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Previewsfurther interest to explore its potential
use as a prognostic biomarker to stratify
patients. Tumors with high 14-3-3z may
have an active TGF-b-induced pro-tumor-
igenic response, and patients carrying
these tumors may benefit from TGF-b tar-
geted therapy. Moreover, 14-3-3z could
be explored as a therapeutic target to
specifically interfere with pathogenic ef-
fects of TGF-b. Although protein-protein
interactions are challenging to target,
several compounds that interfere with
14-3-3z signaling have been described,
but, so far, are not so potent and selec-
tive. With 14-3-3z docking with b-catenin,
GLI2, and YAP1, the downstream effec-
tors of the Wnt, Hedgehog, and Hippo
signaling pathways, respectively, andSMAD interactors, 14-3-3z may serve as
a critical integrator of signaling crosstalk
with the TGF-b/SMAD pathway.REFERENCES
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Bonemetastasis often emerges long after the initial dissemination of cancer cells. In this issue ofCancer Cell,
Wang and colleagues demonstrate that disseminated breast cancer cells engage osteogenic niches in the
bone through heterotypic adherins junctions. This interaction activates mTOR signaling in cancer cells and
supports their expansion to micrometastases.Bone metastasis is a frequent and devas-
tating complication among late-stage
breast cancer patients. These lesions are
usually osteolytic in nature,with excessive
osteoclast activities resulting in bone loss,
pathological fracture, and associated
morbidities (Weilbaecher et al., 2011).
Therefore, much of the research on bone
metastasis has focused on the molecular
crosstalk between tumor cells and bone
stroma that drives the hyperactivation of
osteoclasts. Osteoclast-targeting agents
such as bisphosphonates and the RANKL
neutralizing antibody denosumab have
been approved for clinical use to alleviate
bone metastasis-associated symptoms.
Unfortunately, these treatments are insuf-
ficient to reduce metastatic tumor burden
or improve patient survival, highlightingthe need to develop new strategies to pre-
vent or reduce bone metastasis.
Disseminated tumor cells (DTCs) are
frequently detected in the bone marrow
of early-stage breast cancer patients
without overt bone metastasis (Kang and
Pantel, 2013). Curiously, a long latency
period often exists between the initial
diagnosis and treatment of the primary
tumor and the clinical detection of overt
bone metastasis, especially among pa-
tients with estrogen receptor (ER) positive
breast cancer. These findings indicate
a crucial, and yet untapped, therapeutic
window to eliminate the potential seeds
of bone metastasis at the asymptomatic
stage by preventing DTCs from progress-
ing further. Recent studies have begun to
shed light on some of the early events dur-ing bone colonization. For example, Src
activation has been associated with late-
onset bone metastasis of breast cancer
by promoting the survival and outgrowth
of tumor cells (Zhang et al., 2009), while
VCAM1 promotes osteolytic expansion
of indolent bone micrometastasis by re-
cruiting osteoclasts (Lu et al., 2011). Pros-
tate cancer DTCs have been shown to
compete with hematopoietic stem cells
(HSCs) for occupancy in bone niches
(Shiozawa et al., 2011). However, the
cellular composition of the bone stromal
environment that provides a nurturing
niche for DTCs upon their arrival remains
unclear. In this issue of Cancer Cell,
Wang et al. (2015) used a new mouse
model of early bone metastasis, coupled
with in-depth mechanistic studies and, February 9, 2015 ª2015 Elsevier Inc. 153
Figure 1. Different Stages of Bone Metastasis Progression and the Role of the Osteogenic
Niche in the Transition of DTCs to Micrometastases
After dissemination into the bone marrow, DTCs of breast cancer with mesenchymal-like features may
undergo MET to resume an epithelial-like state, regaining the membrane expression of E-cadherin. These
DTCs may exist as dormant solitary cells or engage the osteogenic niches through hAJ interaction
between E-cadherin in tumor cells and N-cadherin in osteogenic cells. This interaction activates mTOR
and AKT signaling through unknown mechanisms and promotes the expansion of DTCs to mullticellular
micrometastasis. Recruitment and activation of osteoclasts by tumor-derived factors further stimulates
transition to overt osteolytic lesions. It is possible that other bone stromal cells and additional intercellular
interactions are required to fulfill the tumor-promoting function of the osteogenic niche. Dotted lines
indicate potential interactions that have not been experimentally elucidated.
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Previewsclinical data analyses, to define an osteo-
genic niche utilized by tumor cells during
the initial step of bone colonization—
the expansion from solitary DTCs to prolif-
erating multi-cellular micrometastases
(Figure 1).
Previous animal models of bonemetas-
tasis are limited by several technical
deficiencies. The low efficiency of the
spontaneous bone metastasis from pri-
mary tumors prevents robust quantitative
analysis. Inoculation of tumor cells into cir-
culation by intracardiac or into bone by154 Cancer Cell 27, February 9, 2015 ª2015intratibial injection generates excessive
extraskeletal lesions or damages the local
bone microenvironment, respectively. To
overcome these problems, the authors
developed an intrailiac artery (IIA) injection
method to deliver cancer cells to hind
limbs, thus allowing for the enrichment
of early-stage bone metastasis without
affecting other organs. Imaging analysis
revealed that alkaline phosphatase- and
collagen I-positive osteoblastic lineage
cells were detected in high frequencies
within one-cell distance of multicellularElsevier Inc.micrometastases, while cathepsin K-pos-
itive osteoclasts are often absent. Consis-
tently, osteogenic rather than osteolytic
features were observed in these niches.
The cellular composition of these early
‘‘osteogenic niches’’ indicates a pre-os-
teolytic stage during bone metastasis
development, prior to the emergence of
osteolytic lesions commonly seen in overt
bone metastasis (Figure 1).
In vitro co-culture and in vivo co-injec-
tion assays revealed that osteogenic
mesenchymal stromal cells (MSCs) pro-
moted tumor proliferation in a contact-
dependent manner. Focusing on cell-cell
junctions that might be important for
such tumor-niche interactions, the au-
thors discovered that heterotypic adher-
ins junctions (hAJs) formed between
E-cadherin in tumor cells and N-cadherin
in osteogenic cells were responsible for
the tumor-promoting effect (Figure 1).
Disruption of hAJ by anti-E-cadherin anti-
body or dominant negative E-cadherin
strongly inhibited bone metastasis forma-
tion without affecting primary tumor
growth, suggesting a specific window for
targeting hAJs in early bone colonization.
To define the link between E-cadherin
status and bone metastasis risk in human
breast cancer, Wang et al. (2015) interro-
gated multiple breast cancer microarray
datasets and showed that E-cadherin
expression is significantly higher in the
luminal subtypes of breast cancer
compared to non-luminal tumors, and a
high E-cadherin level is associated with
increased risk of bone metastasis. These
findings are consistent with the clinical
observation that bone metastasis most
frequently occurs in luminal breast can-
cers, which are typically ER+. Paradoxi-
cally, loss of E-cadherin expression has
long been recognized as a hallmark of
epithelial-mesenchymal transition (EMT),
an important process during tumor inva-
sion and metastasis. Recent studies in
animal models have indicated that the
reverse process, mesenchymal-epithelial
transition (MET), may be equally essential
for DTCs to regain proliferation potential
during metastatic colonization (Tsai
et al., 2012). Thus, the specific functional
role of E-cadherin in bone micrometasta-
sis formation supports the model that
the epithelial state is more favorable for
the growth of both primary tumors and
metastasis, while the mesenchymal-like
phenotypemay be a transient state during
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Previewstumor invasion and dissemination (Bra-
bletz, 2012). Whether hAJs play an
equally essential role in the formation of
early metastatic niches in other organs
should be explored in future research,
since it is plausible that E-cadherin+
tumor cells may also form hAJs with
other N-cadherin+ stromal cells from
the mesenchymal lineage. Moreover,
rigorous genetic ablation analysis of spe-
cific cell types and pathway components,
a gold standard in HSC niche studies
(Morrison and Scadden, 2014), should
also be adopted for validating functional
elements of metastatic niches.
The authors further identified mTOR
and AKT as key kinase pathways acti-
vated in cancer cells within osteogenic
niches, although it remains unclear how
hAJs activate these kinases. Consistently,
mTOR activity was found to be signifi-
cantly higher in established bone macro-
metastases compared to solitary DTCs
in patient samples. Moreover, genetic or
pharmacological inhibition of mTOR
signaling blocked the transition of solitary
DTCs to micrometastases in the bone.
These results suggest the potential appli-
cation of mTOR inhibitors such as rapa-
mycin and Torin 1 for the prevention of
bone metastasis. However, the immuno-
suppressive effect of mTOR inhibitors
may require extra caution when applying
such treatment to prevent metastatic
recurrence. It is likely that other contact-dependent or paracrine signaling mecha-
nisms, as well as other stromal cell types,
may also contribute essential functions to
the metastasis-fostering functions of the
niche. For example, it has been shown
recently that DTCs are kept dormant in
perivascular niches until sprouting neo-
vasculature stimulates their outgrowth
(Ghajar et al., 2013). Identification of these
mechanisms may reveal new avenues
for developing targeted therapeutics.
Furthermore, because animal experi-
ments indicated that mTOR inhibitors
were only effective in blocking early-stage
bone colonization, the timing and duration
of the clinical application of osteogenic
niche targeting agents in the adjuvant
setting would need to be evaluated
thoroughly.
By defining the osteogenic niches for
micrometastases as an intermediate
stage between solitary DTCs and osteo-
lytic metastasis, the study by Wang et al.
(2015) filled an important gap in our un-
derstanding of bone metastasis develop-
ment. There are many open questions, in
addition to those mentioned earlier, for
future exploration. How does the growth
and therapeutic treatment of primary
tumors affect the composition of osteo-
genic niches and subsequent bone
metastasis formation? Does occupation
and utilization of osteogenic niches by tu-
mor cells alter the physiological function
of bone niches in supporting HSC andCancer Cell 27MSC functions and, further, do these
alterations have a systemic impact on tu-
mor progression? By addressing these
questions, more effective strategies
may be developed to combat metastatic
recurrence of breast cancer.REFERENCES
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